Key Highlights

  • Genmab (NASDAQ:GMAB) closed up 28.25% on October 28, 2026 after a Phase 3 trial of petosemtamab with pembrolizumab showed a 50% reduction in the risk of death in head and neck cancer, shares touching +29.9% intraday.
  • Axogen (NASDAQ:AXGN) rose 31.5% on October 28, 2026 after raising its full-year revenue forecast to at least USD 290 million, with third-quarter revenue growing 26.2% from a year earlier, per the company release.
  • OrthoPediatrics (NASDAQ:KIDS) rose 30.6% intraday as of about 3 p.m. ET on October 28, 2026 after record third-quarter revenue of USD 72.7 million, up 19%, and a raised forecast of USD 270 million to USD 273 million.
  • Replimune (NASDAQ:REPL) rose 23.8% on October 28, 2026 after fiscal second-quarter results, with its cancer therapy said to be available in the United States since early October. The link to the move is our inference.

Genmab (NASDAQ:GMAB): Phase 3 Survival Win in Head and Neck Cancer

Genmab said on October 28, 2026 that a Phase 3 trial of its investigational therapy petosemtamab met its goal in head and neck cancer. The company reported a 50% reduction in the risk of death for patients who received petosemtamab plus pembrolizumab, compared with pembrolizumab alone. A 50% reduction means the hazard ratio for death was about 0.5, a relative figure and not a promise that half of patients survive. The shares closed up 28.25% and reached +29.9% intraday, according to published market data. The details come from the company release as summarized, so median survival, confidence intervals and side effects are not covered here. For Genmab (NASDAQ:GMAB), the risk is that the full data are less impressive than the headline and that regulators ask for more evidence. Phase 3 trials are the large, controlled studies regulators usually rely on, so a clear survival benefit can support an application for approval. Head and neck cancer is a difficult disease with limited treatment options, which is why a survival signal moves stocks sharply. Genmab is a Danish biotech that trades in the United States as depositary shares, and a medical-meeting presentation would be the next test.

Axogen (NASDAQ:AXGN): Raised Forecast and 26.2% Growth

Axogen reported third-quarter results on October 28, 2026 and raised its full-year revenue forecast to at least USD 290 million, according to the company release. Third-quarter revenue grew 26.2% from a year earlier, and the shares rose 31.5% on the day. The company makes products used in nerve repair, a niche medical-device market, and smaller companies react sharply to guidance because fewer analysts cover them. The phrase at least USD 290 million leaves room for a stronger fourth quarter. The prior forecast, the third-quarter revenue in dollars and profit figures were not in the information reviewed, so the size of the raise cannot be calculated. After a 31.5% gain, Axogen (NASDAQ:AXGN) must now deliver a fourth quarter that supports the higher floor. Raising guidance after strong quarterly growth tells investors that management sees the trend continuing, which can lift expected earnings and valuations. Medical-device companies also face regulatory and pricing pressure, so margins, cash and any one-time items in the company release deserve a check. Analyst estimate changes in the days ahead and the fourth-quarter report are the next signals.

OrthoPediatrics (NASDAQ:KIDS): Record Sales of USD 72.7 Million

OrthoPediatrics reported record third-quarter revenue of USD 72.7 million on October 28, 2026, up 19% from a year earlier, and raised its full-year revenue forecast to a range of USD 270 million to USD 273 million, according to the company release. The shares were up 30.6% at about 3 p.m. ET, so the closing move may differ. Dividing USD 72.7 million by 1.19, our own arithmetic, puts the prior-year quarter near USD 61.1 million, an increase of about USD 11.6 million. The company makes orthopedic implants and instruments designed for children, a specialized niche. Profit figures, cash and the prior forecast range were not reviewed. The risk for OrthoPediatrics (NASDAQ:KIDS) is that a cautious hospital purchasing cycle would show up quickly in revenue. Record revenue shows demand is still rising, and growth of 19% suggests the company is gaining share or expanding hospital adoption in a niche market. The forecast range of USD 270 million to USD 273 million is narrow, which signals management confidence in visibility. Guidance that rises alongside results often prompts analysts to lift estimates, and the final closing price should be checked.

Replimune (NASDAQ:REPL): Launch-Stage Cancer Therapy Draws Buyers

Replimune reported fiscal second-quarter results on October 28, 2026, and the shares rose 23.8% on the day, according to published market data. In the release, the company said its cancer therapy has been available in the United States since early October. No cause was stated for the share move, so the connection to the launch is our inference. Revenue, the net loss and the cash balance were not in the data reviewed. Because the quarter ended before the launch, meaningful sales would appear in later reports. A commercial launch raises costs for sales staff and manufacturing, and biotechs often raise equity after a strong share move, which can dilute holders. Early prescriptions and insurer coverage are the key tests for Replimune (NASDAQ:REPL). For a clinical-stage biotech, moving to a commercial product changes the story: the stock stops trading only on trial news, and investors begin to track prescriptions, sales and pricing. Early uptake often shapes expectations for years, and doctors must be persuaded to prescribe a new therapy. A slow start could prompt management to revise spending plans.

Where Things Stand

A raised forecast, a survival result, record sales and a product launch gave each stock a different reason to rise, and all four now carry higher expectations. Genmab (NASDAQ:GMAB) has the clearest efficacy signal. Axogen (NASDAQ:AXGN) raised its forecast floor to USD 290 million. OrthoPediatrics (NASDAQ:KIDS) raised its range to USD 270 million to USD 273 million. Replimune (NASDAQ:REPL) has a launch with no stated cause for its move. The next catalysts are full trial data for Genmab, the fourth-quarter reports for the device makers and early sales for Replimune. Large one-day gains can reverse if details disappoint.